{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:01:59Z","timestamp":1772762519067,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00702-013-1127-5","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T11:27:21Z","timestamp":1386242841000},"page":"513-519","source":"Crossref","is-referenced-by-count":33,"title":["Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis"],"prefix":"10.1007","volume":"121","author":[{"given":"Harald","family":"Hefter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanze","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,6]]},"reference":[{"key":"1127_CR1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","volume":"26","author":"R Benecke","year":"2012","unstructured":"Benecke R (2012) Clinical relevance of botulinum toxin immunogenicity. BioDrugs 26:e1\u2013e9","journal-title":"BioDrugs"},{"key":"1127_CR2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1531-8257(200001)15:1<146::AID-MDS1023>3.0.CO;2-X","volume":"15","author":"F Birklein","year":"2000","unstructured":"Birklein F, Erbguth F (2000) Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A\u2014a preliminary observation. Mov Disord 15:146\u2013149","journal-title":"Mov Disord"},{"key":"1127_CR3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353\u20131360","journal-title":"Mov Disord"},{"key":"1127_CR4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"308","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308:103\u2013109","journal-title":"J Neurol Sci"},{"key":"1127_CR5","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/mds.21051","volume":"21","author":"C Cordivari","year":"2006","unstructured":"Cordivari C, Misra VP, Vincent A, Catania S, Bhatia K, Lees AJ (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21:1737\u20131741","journal-title":"Mov Disord"},{"issue":"Suppl. 8","key":"1127_CR6","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","volume":"19","author":"D Dressler","year":"2004","unstructured":"Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19(Suppl. 8):S92\u2013S100","journal-title":"Mov Disord"},{"issue":"Suppl. 1","key":"1127_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","volume":"11","author":"D Dressler","year":"2006","unstructured":"Dressler D, Hallett M (2006) Immunological aspects of Botox\u00ae, Dysport\u00ae and Myobloc\u2122\/NeuroBloc\u00ae. Eur J Neurol 11(Suppl. 1):11\u201315","journal-title":"Eur J Neurol"},{"key":"1127_CR8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/1531-8257(200009)15:5<973::AID-MDS1031>3.0.CO;2-X","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D, Dirnberger G, Bhatia K, Irmer A, Quinn NP, Bigalke H, Marsden CD (2000) Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord 15:973\u2013976","journal-title":"Mov Disord"},{"key":"1127_CR9","first-page":"394","volume":"10","author":"C Duane","year":"1995","unstructured":"Duane C, Clark M, LaPointe L, Case JLMD (1995) Botulinum toxin A antibodies in initial and delayed resistance to botulinum toxin A therapy in cervical dystonia. Mov Disord 10:394 (abstract)","journal-title":"Mov Disord"},{"key":"1127_CR10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfahrt K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2014therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"1127_CR11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.870070109","volume":"7","author":"P Greene","year":"1992","unstructured":"Greene P, Fahn S (1992) Development of antibodies to botulinum toxin type A in torticollis patients treated with botulinum toxin injections. Mov Disord 7:134 (abstract)","journal-title":"Mov Disord"},{"key":"1127_CR12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213\u2013217","journal-title":"Mov Disord"},{"key":"1127_CR13","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","volume":"50","author":"P Hanna","year":"1998","unstructured":"Hanna P, Jankovic J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50:1624\u20131629","journal-title":"Neurology"},{"key":"1127_CR14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jnnp.66.5.612","volume":"66","author":"PA Hanna","year":"1999","unstructured":"Hanna PA, Jankovic J, Vincent A (1999) Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 66:612\u2013616","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1127_CR15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870120116","volume":"12","author":"KR Kessler","year":"1997","unstructured":"Kessler KR, Benecke R (1997) The EDB test\u2014a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12:95\u201399","journal-title":"Mov Disord"},{"key":"1127_CR16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","volume":"246","author":"KR Kessler","year":"1999","unstructured":"Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 246:265\u2013274","journal-title":"J Neurol"},{"key":"1127_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1212\/01.wnl.0000287087.99612.e5","volume":"70","author":"G Kranz","year":"2008","unstructured":"Kranz G, Sycha T, Voller B, Kranz GS, Schnider P, Auff E (2008) Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology 70:133\u2013136","journal-title":"Neurology"},{"key":"1127_CR18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","volume":"32","author":"O Lange","year":"2009","unstructured":"Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213\u2013218","journal-title":"Clin Neuropharmacol"},{"key":"1127_CR19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/174313209X405137","volume":"31","author":"B Mohammadi","year":"2009","unstructured":"Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31:463\u2013466","journal-title":"Neurol Res"},{"key":"1127_CR20","first-page":"28","volume-title":"Handbook of botulinum toxin treatment","author":"P Moore","year":"2003","unstructured":"Moore P, Naumann M (2003) General and clinical aspects of treatment with botulinum toxin. In: Moore P, Naumann M (eds) Handbook of botulinum toxin treatment, 2nd edn. Blackwell, Malden, pp 28\u201375","edition":"2"},{"key":"1127_CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","volume":"120","author":"M Naumann","year":"2013","unstructured":"Naumann M, Boo LM, Ackerman AH, Gallagher CJ (2013) Immunogenicity of botulinum toxins. J Neural Transm 120:275\u2013290","journal-title":"J Neural Transm"},{"key":"1127_CR22","first-page":"968","volume":"10","author":"MS Nestor","year":"2011","unstructured":"Nestor MS, Ablon GR (2011) The frontalis activity measurement standard: a novel contralateral method for assessing botulinum neurotoxin type-A activity. J Drugs Dermatol 10:968\u2013972","journal-title":"J Drugs Dermatol"},{"key":"1127_CR23","doi-asserted-by":"crossref","first-page":"575.e13","DOI":"10.1016\/j.urology.2007.01.030","volume":"69","author":"H Schulte-Baukloh","year":"2007","unstructured":"Schulte-Baukloh H, Bigalke H, Heine G, Pape D, Stuerzebecher B, Miller K, Knispel HH (2007) Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection. Urology 69:575.e13\u2013575.e15","journal-title":"Urology"},{"key":"1127_CR24","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M et al (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699\u20131706","journal-title":"Neurology"},{"key":"1127_CR25","volume-title":"Effect of different injection strategies for long-term treatment of cervical dystonia with botulinum toxin A (in German)","author":"C Spiess","year":"2005","unstructured":"Spiess C (2005) Effect of different injection strategies for long-term treatment of cervical dystonia with botulinum toxin A (in German). University of D\u00fcsseldorf, D\u00fcsseldorf"},{"key":"1127_CR26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"2","author":"JK Tsui","year":"1986","unstructured":"Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2:245\u2013247","journal-title":"Lancet"},{"key":"1127_CR27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/mds.20073","volume":"19","author":"B Voller","year":"2004","unstructured":"Voller B, Moraru E, Auff E, Benesch M, Poewe W, Wissel J et al (2004) Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A. Mov Disord 19:943\u2013947","journal-title":"Mov Disord"},{"key":"1127_CR28","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1212\/WNL.43.9.1715","volume":"43","author":"M Zuber","year":"1993","unstructured":"Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43:1715\u20131718","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1127-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-1127-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1127-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T18:52:01Z","timestamp":1553626321000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-1127-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1127"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-1127-5","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}